JP2023519501A5 - - Google Patents

Info

Publication number
JP2023519501A5
JP2023519501A5 JP2022552307A JP2022552307A JP2023519501A5 JP 2023519501 A5 JP2023519501 A5 JP 2023519501A5 JP 2022552307 A JP2022552307 A JP 2022552307A JP 2022552307 A JP2022552307 A JP 2022552307A JP 2023519501 A5 JP2023519501 A5 JP 2023519501A5
Authority
JP
Japan
Prior art keywords
oligomer compound
pharmaceutical composition
weeks
composition according
once
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022552307A
Other languages
English (en)
Japanese (ja)
Other versions
JP7795467B2 (ja
JP2023519501A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/022069 external-priority patent/WO2021183857A1/en
Publication of JP2023519501A publication Critical patent/JP2023519501A/ja
Publication of JP2023519501A5 publication Critical patent/JP2023519501A5/ja
Priority to JP2025266910A priority Critical patent/JP2026048915A/ja
Application granted granted Critical
Publication of JP7795467B2 publication Critical patent/JP7795467B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022552307A 2020-03-13 2021-03-12 プレカリクレイン関連の状態を治療及び予防するための組成物及び方法 Active JP7795467B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025266910A JP2026048915A (ja) 2020-03-13 2025-12-19 プレカリクレイン関連の状態を治療及び予防するための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062989427P 2020-03-13 2020-03-13
US62/989,427 2020-03-13
PCT/US2021/022069 WO2021183857A1 (en) 2020-03-13 2021-03-12 Compositions and methods for treating and preventing prekallikrein-associated conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025266910A Division JP2026048915A (ja) 2020-03-13 2025-12-19 プレカリクレイン関連の状態を治療及び予防するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2023519501A JP2023519501A (ja) 2023-05-11
JP2023519501A5 true JP2023519501A5 (enExample) 2024-03-26
JP7795467B2 JP7795467B2 (ja) 2026-01-07

Family

ID=77672313

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022552307A Active JP7795467B2 (ja) 2020-03-13 2021-03-12 プレカリクレイン関連の状態を治療及び予防するための組成物及び方法
JP2025266910A Pending JP2026048915A (ja) 2020-03-13 2025-12-19 プレカリクレイン関連の状態を治療及び予防するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025266910A Pending JP2026048915A (ja) 2020-03-13 2025-12-19 プレカリクレイン関連の状態を治療及び予防するための組成物及び方法

Country Status (10)

Country Link
US (2) US20230149438A1 (enExample)
EP (1) EP4118208A4 (enExample)
JP (2) JP7795467B2 (enExample)
KR (1) KR20220152569A (enExample)
CN (1) CN115244179A (enExample)
AU (2) AU2021233914B2 (enExample)
BR (1) BR112022016167A2 (enExample)
IL (1) IL295631B1 (enExample)
MX (1) MX2022011205A (enExample)
WO (1) WO2021183857A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9670492B2 (en) 2013-08-28 2017-06-06 Ionis Pharmaceuticals, Inc. Modulation of prekallikrein (PKK) expression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9670492B2 (en) * 2013-08-28 2017-06-06 Ionis Pharmaceuticals, Inc. Modulation of prekallikrein (PKK) expression
HUE052709T2 (hu) * 2014-05-01 2021-05-28 Ionis Pharmaceuticals Inc Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására
ES2982752T3 (es) * 2015-10-22 2024-10-17 Iltoo Pharma Composiciones farmacéuticas de il-2
LT4119569T (lt) * 2015-11-06 2024-09-25 Ionis Pharmaceuticals, Inc. Konjuguoti priešprasmiai junginiai, skirti panaudoti terapijoje
US11286307B2 (en) * 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
WO2018148449A1 (en) * 2017-02-08 2018-08-16 Ionis Pharmaceuticals, Inc. Modulation of kallikrein b1 (klkb1) for treatment of headache

Similar Documents

Publication Publication Date Title
CN105311029A (zh) 抗肿瘤活性的喹啉衍生物
Maspero et al. Long-term safety of dupilumab in patients with moderate-to-severe asthma: TRAVERSE continuation study
KR20230038644A (ko) 코로나바이러스 치료를 위한 피르페니돈
JP2022533981A5 (enExample)
CN112638378A (zh) 用于根除幽门螺杆菌的组合物
US20240277811A1 (en) Methods for treating obstructive sleep apnea
JP7639156B2 (ja) チルゼパチド治療方法
TW202444371A (zh) 嚴重發熱伴血小板減少症候群病毒感染症之治療劑
Harfouch et al. Therapeutic approaches for COVID 19: Challenges and successes
JP2017508737A5 (enExample)
US20250332136A1 (en) Composition and methods for treatment or prophylaxis of coronavirus and cancers
CN110433160A (zh) 一种治疗肝纤维化的化合物及其应用
CN111467348A (zh) 一种n-(噻唑-2-基)-3-(哌嗪-1-基)丙酰胺类衍生物在药物制备中的应用
US8198293B2 (en) Oxymatrine compositions and related methods for treating and preventing chronic infectious diseases
CN112826820B (zh) Nlrp3抑制剂及其应用
CN114272254B (zh) 甘草次酸和芍药苷的组合在治疗肝损伤、肝纤维化中的应用
JP2024506041A (ja) 潰瘍性大腸炎を予防、処置、または改善するためのアミセリモド
JP7795467B2 (ja) プレカリクレイン関連の状態を治療及び予防するための組成物及び方法
US6194460B1 (en) Composition for treating cough induced by angiotensin converting enzyme inhibitors
CN115969828B (zh) 替拉曲可在制备预防和/或治疗黄热病毒感染的药物中的应用
CN103705748B (zh) 一种治疗肩手综合征的药剂
EP2307018B1 (en) Oxymatrine compositions and use thereof for treating and preventing chronic infectious diseases
HK40094222A (en) Amiselimod for preventing, treating, or ameliorating ulcerative colitis
CN114569618A (zh) 一种头孢克洛的复方制剂及制备方法
CN102149389A (zh) 生物素化艾屈肝素用于降低抗血栓治疗期间出血发生率的用途